Compounds that protect neurons in the brain after a traumatic brain injury

Tech ID:
2006.023.HSCS
Description:

A researcher in the School of Medicine at The University of Texas Health Science Center at San Antonio received a U.S. patent Dec. 31, 2013 for an invention related to his discovery that a class of compounds is protective against traumatic brain injury (TBI). The patent, No. 8,618,074, covers novel methods of preventing or treating neuronal damage, and work is continuing on development of potential therapies for TBI based on this invention.

James D. Lechleiter, Ph.D., professor of cellular and structural biology at the Health Science Center, reported the findings in cell and animal models in peer-reviewed journals. Studies yet to be published extend the results to human brain tissue obtained from patients who underwent temporal lobectomies to curb treatment-resistant epilepsy.

 


He found that two compounds stimulate the ability of the brain’s caretaker cells (called astrocytes) to do their job. The compounds, called 2-methylthio-ADP and MRS2365, are among a class of compounds called purinergic receptor ligands.

External signs and symptoms of TBI are not always present or can go unnoticed in stressful situations such as war, car accidents or many sport-related injuries. Because the skull is a defined space, there is no place to expand. Edema pushes the brain aside, placing pressure on the neurons and tissues.

“Undiagnosed traumatic brain injuries are time bombs,” Dr. Lechleiter said. “This injury continues in the brain. Sometimes, people do not recognize or admit that they are having problems. Others may not understand why they are having problems and what their problems are, which can make them nervous and upset. In the case of soldiers wounded in war, the trauma happens in Afghanistan, but you carry it home.”

 

Full Press Release: http://uthscsa.edu/hscnews/singleformat2.asp?newID=4696

Issued U.S. Patent No. 8,618,074: http://tinyurl.com/Lechleiter-Patent

Relevent Publications:

J Cereb Blood Flow Metab. 2013 Apr;33(4):600-11. doi: 10.1038/jcbfm.2012.214. Epub 2013 Jan 16.P2Y1R-initiated, IP3R-dependent stimulation of astrocyte mitochondrial metabolism reduces and partially reverses ischemic neuronal damage in mouse. Zheng W, Talley Watts L, Holstein DM, Wewer J, Lechleiter JD.  http://www.nature.com/jcbfm/journal/v33/n4/full/jcbfm2012214a.html

J Neurotrauma. 2013 Jan 1;30(1):55-66. doi: 10.1089/neu.2012.2488.Purinergic 2Y1 receptor stimulation decreases cerebral edema and reactive gliosis in a traumatic brain injury model. Talley Watts L, Sprague S, Zheng W, Garling RJ, Jimenez D, Digicaylioglu M, Lechleiter J. http://online.liebertpub.com/doi/abs/10.1089/neu.2012.2488

 
Patent Information:
Category(s):
Biologics
Therapeutics
For Information, Contact:
Christine Burke
Senior Technology Licensing Associate
Ofc of Technology Transfer and Commercialization
210-562-4038
burkec@uthscsa.edu
Inventors:
James Lechleiter
Keywords:
Biologics